mCRC & Regorafenib | TCT 2021 | National Marrow Donor Program Trial ResultsMay 05, 2021 | Oncology Internal Medicine Cases in the Management of Metastatic Colorectal Cancer: Rechallenge With Chemotherapy After Regorafenib in a Patient With RAS/BRAF Wild-Type Disease The third case in a three-part series, this article chronicles the treatment journey of a 50-year-old male patient who had been diagnosed with left-sided colon cancer in January 2016. After multiple FOLFOX doses, FOLFIRI cycles, and resection, the patient began treatment with regorafenib in July 2020 as a third-line treatment, with the hope that this agent could potentially re-sensitize the tumor to subsequent anti–epidermal growth factor receptor (EGFR) therapy. Read full article Hematology Highlights in Graft-vs-Host Disease From the 2021 Transplantation & Cellular Therapy (TCT) Meetings of the ASTCT and the CIBMTR From the pages of Clinical Advances in Hematology & Oncology comes this review of selected presentations from the 2021 TCT Meetings Digital Experience, which took place February 8-12, 2021. Expert commentary is provided by Dr. Yi-Bin Chen, Director of the Hematopoietic Cell Transplant & Cellular Therapy Program at Massachusetts General Hospital. Read full article Hematology National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide In this Original Report from the Journal of Clinical Oncology, the authors hypothesized that hematopoietic cell transplantation (HCT) with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT. Was their hypothesis correct? Read full article
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH